These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37800725)

  • 1. Yes-Associated Protein Mediates the Transition from Inflammation to Fibrosis in Graves' Orbitopathy.
    Ko J; Kim YJ; Choi SH; Lee CS; Yoon JS
    Thyroid; 2023 Dec; 33(12):1465-1475. PubMed ID: 37800725
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential Therapeutic Role of Bone Morphogenic Protein 7 (BMP7) in the Pathogenesis of Graves' Orbitopathy.
    Kim BY; Choi SH; Kim JY; Ko J; Yook JI; Kim HS; Lee EJ; Kikkawa DO; Yoon JS
    Invest Ophthalmol Vis Sci; 2022 Jun; 63(6):7. PubMed ID: 35671049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of microRNA-146a in regulation of fibrosis in orbital fibroblasts from patients with Graves' orbitopathy.
    Jang SY; Park SJ; Chae MK; Lee JH; Lee EJ; Yoon JS
    Br J Ophthalmol; 2018 Mar; 102(3):407-414. PubMed ID: 29101123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dihydroartemisinin Exerts Antifibrotic and Anti-Inflammatory Effects in Graves' Ophthalmopathy by Targeting Orbital Fibroblasts.
    Yang S; Wang X; Xiao W; Xu Z; Ye H; Sha X; Yang H
    Front Endocrinol (Lausanne); 2022; 13():891922. PubMed ID: 35663306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Inositol-Requiring Enzyme 1 and Autophagy in the Pro-Fibrotic Mechanism Underlying Graves' Orbitopathy.
    Lee CE; Kim JY; Yoon JS; Ko J
    Yonsei Med J; 2024 Jul; 65(7):397-405. PubMed ID: 38910302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sphingosine-1-Phosphate Mediates Fibrosis in Orbital Fibroblasts in Graves' Orbitopathy.
    Ko J; Chae MK; Lee JH; Lee EJ; Yoon JS
    Invest Ophthalmol Vis Sci; 2017 May; 58(5):2544-2553. PubMed ID: 28492873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Potential of Targeting Periostin in the Treatment of Graves' Orbitopathy.
    Jang SY; Kim J; Park JT; Liu CY; Korn BS; Kikkawa DO; Lee EJ; Yoon JS
    Front Endocrinol (Lausanne); 2022; 13():900791. PubMed ID: 35707463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of fibroblast growth factor 10 with the fibrotic and inflammatory pathogenesis of Graves' orbitopathy.
    Jang SY; Choi SH; Kikkawa D; Lee EJ; Yoon JS
    PLoS One; 2021; 16(8):e0255344. PubMed ID: 34383782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of Graves' orbitopathy.
    Yoon JS; Chae MK; Jang SY; Lee SY; Lee EJ
    Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5921-9. PubMed ID: 22871832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic role of histone deacetylase inhibition in an
    Byeon HJ; Choi SH; Kikkawa DO; Ko J; Yoon JS
    Mol Med Rep; 2024 Dec; 30(6):. PubMed ID: 39329199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M1-Like Macrophages Modulate Fibrosis and Inflammation of Orbital Fibroblasts in Graves' Orbitopathy: Potential Relevance to Soluble Interleukin-6 Receptor.
    Lu Y; Wang Y; Wang Y; Wu Y; Huang Y; Liu X; Zhang S; Zhong S; Li Y; Li B; Sun J; Fang S; Zhou H
    Thyroid; 2023 Mar; 33(3):338-350. PubMed ID: 36617890
    [No Abstract]   [Full Text] [Related]  

  • 12. Disulfiram Exerts Antiadipogenic, Anti-Inflammatory, and Antifibrotic Therapeutic Effects in an
    Wang X; Yang S; Ye H; Chen J; Shi L; Feng L; Wang X; Zhang T; Chen R; Xiao W; Yang H
    Thyroid; 2022 Mar; 32(3):294-305. PubMed ID: 34605662
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves' Orbitopathy in Orbital Fibroblasts.
    Lee GE; Kim J; Lee JS; Ko J; Lee EJ; Yoon JS
    Front Endocrinol (Lausanne); 2020; 11():607144. PubMed ID: 33488522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokine Expression during Adipogenesis and Inflammation in Orbital Fibroblasts from Patients with Graves' Orbitopathy.
    Lee CE; Choi SH; Yoon JS
    Korean J Ophthalmol; 2020 Jun; 34(3):192-202. PubMed ID: 32495527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect of selective interleukin-2-inducible tyrosine kinase inhibitor in orbital fibroblasts from patients with Graves' orbitopathy.
    Yoon Y; Park HY; Chae MK; Jang SY; Yoon JS
    Endocr J; 2024 Sep; 71(9):851-861. PubMed ID: 38866492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of miR-146a in the Regulation of Inflammation in an In Vitro Model of Graves' Orbitopathy.
    Jang SY; Chae MK; Lee JH; Lee EJ; Yoon JS
    Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):4027-34. PubMed ID: 27494344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Mobility Group Box 1 Is Associated with the Inflammatory Pathogenesis of Graves' Orbitopathy.
    Han SY; Choi SH; Shin JS; Lee EJ; Han SH; Yoon JS
    Thyroid; 2019 Jun; 29(6):868-878. PubMed ID: 30973094
    [No Abstract]   [Full Text] [Related]  

  • 18. Histone Deacetylase 4 Controls Extracellular Matrix Production in Orbital Fibroblasts from Graves' Ophthalmopathy Patients.
    Ekronarongchai S; Palaga T; Saonanon P; Pruksakorn V; Hirankarn N; van Hagen PM; Dik WA; Virakul S
    Thyroid; 2021 Oct; 31(10):1566-1576. PubMed ID: 34235979
    [No Abstract]   [Full Text] [Related]  

  • 19. Pentraxin 3 mediates inflammation and adipogenesis in Graves' orbitopathy pathogenesis.
    Kim MS; Park HY; Choi SH; Chang EJ; Ko J; Yoon JS
    J Mol Endocrinol; 2024 Nov; 73(4):. PubMed ID: 39283923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunophenotype of Lacrimal Glands in Graves Orbitopathy: Implications for the Pathogenesis of Th1 and Th17 Immunity.
    Huang Y; Wu Y; Zhang S; Lu Y; Wang Y; Liu X; Zhong S; Wang Y; Li Y; Sun J; Fang S; Zhou H
    Thyroid; 2022 Aug; 32(8):949-961. PubMed ID: 35469435
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.